- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/22 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p. ex. Acinetobacter
Détention brevets de la classe C07K 14/22
Brevets de cette classe: 308
Historique des publications depuis 10 ans
|
27
|
16
|
30
|
24
|
21
|
19
|
18
|
15
|
14
|
14
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1650 |
55 |
| Pfizer Inc. | 3401 |
34 |
| The Regents of the University of California | 20289 |
19 |
| Aridis Pharmaceuticals Inc. | 26 |
10 |
| Children's Hospital & Research Center at Oakland | 58 |
9 |
| Wyeth LLC | 652 |
8 |
| Wyeth Holdings LLC | 51 |
7 |
| Novartis AG | 10623 |
6 |
| Griffith University | 158 |
5 |
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | 377 |
5 |
| Oxford University Innovation Limited | 1576 |
5 |
| Engineered Antigens Inc. | 12 |
5 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2215 |
4 |
| MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. | 23 |
4 |
| Sanofi Pasteur Inc. | 377 |
4 |
| Serum Institute of India Private Limited | 102 |
4 |
| T2 Biosystems, Inc. | 115 |
4 |
| University of Massachusetts | 2257 |
4 |
| Cansino Biologics Inc. | 77 |
4 |
| Asociación Centro de Investigación Cooperativa en Biociencias-cic Biogune | 50 |
3 |
| Autres propriétaires | 109 |